english.prescrire.org > Prescrire International > N°112 - January 2011

n°112

January 2011

Issue Contents
Editorial

Free  Personalised service

p.4

New Products


13-valent pneumococcal conjugate vaccine (New Drug)

p.5-9
Attractive, but close monitoring required

A 10-valent conjugate vaccine for some countries

p.8

Ketoprofen gels (Unacceptable)

p.10
Remain on the market in France and Europe, despite cutaneous adverse effects

Vinflunine (bladder cancer) (New Drug)

p.11-13
No benefit despite statistical manipulation

INN common stems : -dipine

p.13

Adverse Effects


Free  Domperidone: QT prolongation in infants

p.14
Avoid using for mild regurgitation

Neuroleptics: swallowing disorders

p.15-17
Weight loss, potentially fatal aspiration pneumonia

Exenatide: excessive weight loss

p.17
Further undermines its role in type 2 diabetes

Saquinavir: prolongation of PR and QT intervals

p.17
Precautions are required in patients at risk

Reviews


Adverse effects of cannabis

p.18-23
Inform psychologically vulnerable patients of the risk of serious, dose-dependent disorders

Outlook


Free  DSM-V: madness!

p.24
Lower diagnostic thresholds and medicalisation of life

Free  Targeting drug companies' bottom line

p.25
Off-label promotion: shifting a balance of power that benefits industry

End of life. Some patients want to discuss their prognosis and terminal care

p.25-26
A Canadian survey

Free  Book review : Mediator° 150 mg

p.26
About the benfluorex scandal in France

Free  A coherent database of reviews

p.28

Masthead


Free  Masthead

p.2

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe